mercaptopurine 20 MG/ML Oral Suspension [Purixan]

What the CMS Formulary Data Shows for mercaptopurine 20 MG/ML Oral Suspension [Purixan]

Per the CMS 2026 Part D formulary file, mercaptopurine 20 MG/ML Oral Suspension [Purixan] (RxNorm concept RXCUI 1536490, generic name mercaptopurine) appears on 32 distinct formulary files spanning 1,922 Medicare Part D plan offerings - 37.9% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.8.

Real-world access to mercaptopurine 20 MG/ML Oral Suspension [Purixan] depends on utilization management as much as tier placement: 28.1% of covering formularies require prior authorization. 0% require step therapy. 3.1% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 10,603 Part D beneficiaries filled mercaptopurine 20 MG/ML Oral Suspension [Purixan] in 2023, with total plan-and-beneficiary spending of $5,735,426 and an average per-beneficiary annual cost of $540.92. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry mercaptopurine 20 MG/ML Oral Suspension [Purixan] today.